Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel vs Blinatumomab or Inotuzumab in Adult R/R B-ALL
NCT03628053Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Jun 2020
- Primary completion
- Oct 2025
- Modality
- CAR-T Cells
01
Overview
Phase 3, randomised, open-label trial of tisagenlecleucel in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Novartis. Primary endpoint: Overall Survival at 4 years. Planned start Jun 2020; status: withdrawn.
02
Drugs
tisagenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03628053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628053.